Literature DB >> 22585854

Regulating the TRAIL of destruction: how A20 protects glioblastomas from TRAIL-mediated death.

Inge Verbrugge1, Ricky W Johnstone.   

Abstract

In this issue of Cancer Discovery, Bellail and colleagues unravel how overexpression of the ubiquitin-modifying enzyme A20 results in TNF-related apoptosis-inducing ligand (TRAIL) resistance in glioblastoma. After TRAIL receptor stimulation, A20 mediates the polyubiquitination of RIP1 at the TRAIL receptor tail, resulting in the interaction of the polyubiquin chain to procaspase-8 that is recruited to the TRAIL-bound receptors. The inability of ubiquitin-bound procaspase-8 to be dimerized and activated prevents the execution of the apoptotic program. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22585854     DOI: 10.1158/2159-8290.CD-11-0350

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  4 in total

1.  The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.

Authors:  Yimin Wang; Ming Wan; Qingxin Zhou; Hao Wang; Zhidong Wang; Xiangyu Zhong; Lei Zhang; Sheng Tai; Yunfu Cui
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

2.  Exploiting tumor-intrinsic signals to induce mesenchymal stem cell-mediated suicide gene therapy to fight malignant glioma.

Authors:  Man Li; Shoujia Sun; Sean Dangelmajer; Quan Zhang; Junwen Wang; Feng Hu; Fangyong Dong; Ulf D Kahlert; Mingxin Zhu; Ting Lei
Journal:  Stem Cell Res Ther       Date:  2019-03-12       Impact factor: 6.832

3.  Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell lines.

Authors:  Alessia Calzolari; Ernestina Saulle; Maria Laura De Angelis; Luca Pasquini; Alessandra Boe; Federica Pelacchi; Lucia Ricci-Vitiani; Marta Baiocchi; Ugo Testa
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

4.  Effects of silencing RIP1 with siRNA on the biological behavior of the LoVo human colon cancer cell line.

Authors:  Hong-Xia You; Yan-Hong Zhou; Shi-Yun Tan; Tong-Hui She
Journal:  Oncol Lett       Date:  2014-04-07       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.